The current price of MPLT is $6.22 — it has decreased by 7.30% since the previous close. Data as of Nov 5, 2026.
MPLT is down 19.22% over the past week, down 32.97% over the past month and down 61.12% over the past year. The price is below its 200-day moving average of $20.35.
Analysts' average 12-month price target for MPLT is $29.20, which implies 369.45% upside from the current price. Individual estimates range from $13.00 to $46.00.
Of the 15 analysts covering MapLight Therapeutics, Inc., 1 rates it a strong buy, 11 rate it a buy and 3 rate it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
MapLight Therapeutics, Inc. has a market capitalization of $265.08M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, MapLight Therapeutics, Inc. posted a loss of $1.32 per share against an estimate of -$1.35, beating expectations by 2.15%. Upcoming reports are listed in the earnings calendar.
MapLight Therapeutics, Inc. has not paid any dividends over the past year.
Companies most comparable to MapLight Therapeutics, Inc. include Definium Therapeutics, Inc., GH Research PLC, LB Pharmaceuticals Inc Common Stock, Rapport Therapeutics, Inc. Common Stock and Alto Neuroscience, Inc.
In the latest trading session MPLT moved between $6.19 and $6.71, a range of 8.36% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of MapLight Therapeutics, Inc. shows a strong sell rating today and a strong sell rating on the weekly timeframe. Technical ratings are indicators, not investment advice.
Over the past 52 weeks MPLT has traded between $6.19 and $40.43. The current price is 84.62% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.